Results 51 to 60 of about 1,866 (169)

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial [PDF]

, 2023
Bimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis.
Diamant Thaçi, White, K., Vanvoorden, Veerle, White, Katy, Veerle Vanvoorden, Blauvelt, Andrew, Gomez, Natalie Nunez, Katy White, Vanvoorden, V., Gomez, NN, Thaci, Diamant, Mark Lebwohl, Paul, Carle, Kilian Eyerich, Strober, B., Blauvelt, A., Lebwohl, Mark, Andrew Blauvelt, Bruce Strober, Paul, C., White, K, Puig, L, Eyerich, K., Thaci, D, Delphine Deherder, Lebwohl, M, Puig Sanz, Lluís, Blauvelt, A, Deherder, D., Carle Paul, Natalie Nunez Gomez, Lebwohl, M., Strober, Bruce, Strober, B, Deherder, D, Puig, Luis, Vanvoorden, V, Gomez, N.N., Universitat Autònoma de Barcelona, Thaçi, D., Paul, C, Eyerich, Kilian, Luis Puig, Deherder, Delphine   +43 more
core   +1 more source

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.

Journal of American Academy of Dermatology
BACKGROUND Hidradenitis suppurativa (HS) is a chronic inflammatory disease, requiring treatment with durable efficacy and tolerability. OBJECTIVE To report the safety and efficacy of bimekizumab up to 2 years.
Christopher J. Sayed, Brian Kirby, Amit Garg, H. Naik, A. Kimball, C. Zouboulis, G. Jemec, Georgios Kokolakis, John R. Ingram, Akimichi Morita, D. Deherder, C. Crater, Robert L. Rolleri, Tom Vaux, Jérémy Lambert, B. Lukowski, F. Bechara   +16 more
semanticscholar   +1 more source

Inflammatory bowel disease induced by bimekizumab

Gastroenterology Review, 2022
Inflammatory bowel disease (IBD) is a chronic condition of the gastrointestinal tract, with a complex aetiopathogenesis in which genetic, immunological, and environmental factors are being discussed. The development of knowledge about molecular processes and the aetiology of diseases are made possible the implementation of modern therapies with ...
Dominika Wietrzykowska-Grishanovich, Maciej Pleskacz, Radosław Kempiński   +2 more
openaire   +3 more sources

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

RMD Open
Objective To assess the long-term safety profile of bimekizumab (BKZ) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Methods Safety data pooled from six integrated phase IIb/III studies in axSpA and PsA are reported (to ...
P. Mease, L. Gensler, A. Orbai, R. Warren, R. Bajracharya, B. Ink, Alexander Marten, U. Massow, V. Shende, Myriam Manente, L. Peterson, K. White, R. Landewé, D. Poddubnyy   +13 more
semanticscholar   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients

, 2023
A persistent immune-mediated inflammatory disorder called psoriatic arthritis affects about 25% of persons with psoriasis. Bimekizumab, a humanized monoclonal IgG1 antibody, is a novel therapeutic approach that inhibits homodimers and heterodimers of IL ...
Abdelrahman Mohamed Mahmoud (13997365)
core   +1 more source

Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials

Annals of the Rheumatic Diseases
Objectives Acute anterior uveitis (‘uveitis’) is a common axial spondyloarthritis (axSpA) extramusculoskeletal manifestation. Interleukin (IL)-17 is implicated in its pathogenesis, however, there is conflicting evidence for IL-17A inhibition in uveitis ...
Matthew A. Brown, M. Rudwaleit, F. V. van Gaalen, N. Haroon, L. Gensler, C. Fleurinck, Alexander Marten, U. Massow, N. de Peyrecave, T. Vaux, K. White, A. Deodhar, I. E. van der Horst-Bruinsma   +12 more
semanticscholar   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, EarlyView.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source